Modulating allergic response by engineering the major Parietaria allergens.

Attività immunomodulatoria del peptide PAR37 derivato dall'allergene maggiore di Parietaria judaica ParJ1.0101

Fine characterization of immunological mechanisms mediated by the major allergens of Parietaria judaica and by a hypoallergenic hybrid, rPjEDcys.

Allergy is a hypersensitivity disease IgE-mediated, affecting more than 25% of the population. Actually the only curative treatment of allergies is Allergen-Specific Immunotherapy (SIT). Recombinant hypoallergenic allergen derivatives with reduced allergenic activity have been engineered to reduce side effects during SIT. Parietaria judaica (Pj) pollen contains two major allergens, Par j 1 and expressing disulphide bond variants of Par j 1 and Par j 2, was generated. The aim of this research project is to compare the immunological mechanisms activated by the major allergens of Pj and by rPjEDcys. In vitro analysis suggested that rPjEDcys has a reduced allergenity and maintains T cells react…